Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Key Takeaways Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly, acting at GIP, GLP-1, and glucagon receptors [1][3]
Those seeking to support blood sugar and metabolic health
Misleading certifications Some Peaka GLP-1 marketing includes certification logos and seals that suggest FDA approval, GMP compliance, or third-party testing
Your weight loss protocol What to Expect: Significant appetite reduction and reduced food noise within 1 to 2 weeks Average weight loss of 15 to 22% of body weight over the treatment course Possible initial nausea that typically resolves within 2 to 4 weeks (B12 in our formulation helps reduce severity) Gradual dose increases every 4 weeks to minimize side effects Includes: Compounded tirzepatide with B12 and glycine, once-weekly subcutaneous injection All injection supplies (syringes, alcohol swabs) Gradual dose escalation protocol Provider consultations and ongoing monitoring Structured weaning protocol to prevent rebound Free shipping Dosing starts at 2.5mg weekly and increases every 4 weeks based on response and tolerability
US$ 25.32
US$ 22.67
US$ 29.79
US$ 21.79
US$ 25.96
US$ 24.77
US$ 28.22
